International Biotechnology Revenue vs. Return On Asset
| IBT Stock | 684.00 10.00 1.48% |
Total Revenue | First Reported 2004-01-31 | Previous Quarter 16.2 M | Current Value 10.5 M | Quarterly Volatility 12.4 M |
For International Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of International Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well International Biotechnology Trust utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between International Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of International Biotechnology Trust over time as well as its relative position and ranking within its peers.
International |
International Biotechnology Return On Asset vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining International Biotechnology's current stock value. Our valuation model uses many indicators to compare International Biotechnology value to that of its competitors to determine the firm's financial worth. International Biotechnology Trust is rated below average in revenue category among its peers. It also is rated below average in return on asset category among its peers . The ratio of Revenue to Return On Asset for International Biotechnology Trust is about 498,014,888 . At present, International Biotechnology's Total Revenue is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the International Biotechnology's earnings, one of the primary drivers of an investment's value.International Revenue vs. Competition
International Biotechnology Trust is rated below average in revenue category among its peers. Market size based on revenue of Financials industry is currently estimated at about 27.4 Billion. International Biotechnology adds roughly 40.14 Million in revenue claiming only tiny portion of equities under Financials industry.
International Return On Asset vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
International Biotechnology |
| = | 40.14 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
International Biotechnology |
| = | 0.0806 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
International Return On Asset Comparison
International Biotechnology is rated below average in return on asset category among its peers.
International Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in International Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, International Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of International Biotechnology's change in net profit over the period of time. It can combine multiple indicators of International Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 296.1 M | 310.9 M | |
| Operating Income | 37.9 M | 19.7 M | |
| Income Before Tax | 39 M | 19.7 M | |
| Net Income | 38.9 M | 20.4 M | |
| Net Loss | -20.2 M | -19.2 M | |
| Total Other Income Expense Net | 1.1 M | 1.2 M | |
| Income Tax Expense | 135 K | 97.5 K | |
| Net Income From Continuing Ops | 38.9 M | 19.5 M | |
| Net Interest Income | -2 M | -1.9 M | |
| Interest Income | 218 K | 228.9 K | |
| Change To Netincome | 3.9 M | 3.5 M |
International Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on International Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of International Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the International Biotechnology's important profitability drivers and their relationship over time.
Use International Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if International Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in International Biotechnology will appreciate offsetting losses from the drop in the long position's value.International Biotechnology Pair Trading
International Biotechnology Trust Pair Trading Analysis
The ability to find closely correlated positions to International Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace International Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back International Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling International Biotechnology Trust to buy it.
The correlation of International Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as International Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if International Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for International Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your International Biotechnology position
In addition to having International Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Agency Mbs ETFs Thematic Idea Now
Agency Mbs ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agency Mbs ETFs theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agency Mbs ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in International Stock
To fully project International Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of International Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include International Biotechnology's income statement, its balance sheet, and the statement of cash flows.